OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
10
Results
Show all
Save search
Copy query
Show results for
Unknown
(10)
Publication Date
Release Date
2024
(2)
2023
(2)
2022
(2)
2021
(1)
2017
(1)
2014
(1)
2011
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Autonomous assembly of synthetic oligonucleotides built from an expanded DNA alphabet. Total synthesis of a gene encoding kanamycin resistance.
Not available
S-EPMC4222377
|
biostudies-literature
Cite
Recognition of an expanded genetic alphabet by type-II restriction endonucleases and their application to analyze polymerase fidelity.
Not available
S-EPMC3089450
|
biostudies-literature
Cite
Structure and Biophysics for a Six Letter DNA Alphabet that Includes Imidazo[1,2-a]-1,3,5-triazine-2(8H)-4(3H)-dione (X) and 2,4-Diaminopyrimidine (K).
Not available
S-EPMC5831194
|
biostudies-literature
Cite
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Not available
S-EPMC8813065
|
biostudies-literature
Cite
Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO
2
Requirements.
Not available
S-EPMC11434591
|
biostudies-literature
Cite
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
Not available
S-EPMC10314034
|
biostudies-literature
Cite
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.
Not available
S-EPMC8635458
|
biostudies-literature
Cite
Considerations for reporting variants in novel candidate genes identified during clinical genomic testing.
Not available
S-EPMC11456385
|
biostudies-literature
Cite
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Not available
S-EPMC8409066
|
biostudies-literature
Cite
Beyond the exome: What's next in diagnostic testing for Mendelian conditions.
Not available
S-EPMC10432150
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets